Insmed establishes a subsidiary in Japan.

Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.

Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.

Insmed enters into a business combination with Transave, acquiring its late-stage candidate. The new company maintains the name Insmed.

Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.

Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.